Nice Cedex 2

• A Phase 1, multicenter, open-label study of REM-422, a MYB mRNA degrader, in patients with recurrent or metastatic, adenoid cystic carcinoma … Pending
  2023-508476-11-00 1 Adenoid cystic carcinoma (ACC)
• TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma: A single-arm Phas … Pending
  2024-516182-37-01 4 Maintenance treatment in patients with locally advanced/metastatic uro
• A Phase III study evaluating the efficacy of atezoliumab administration in addition to BCG (Bacillus Calmette-Guerin) for 1 year in patient … Pending
  2024-517621-54-00 5 High-risk non-muscle invasive bladder cancer (NMIBC) after transurethr
• A trial to learn how safe durvalumab with chemotherapy is and how well it works in adults with muscle-invasive bladder cancer Pending
  2024-519246-75-01 4 Patients With Muscle-Invasive Bladder Cancer
• Tucatinib and trastuzumab in HER3-mutant and HER2-not amplified metastatic breast cancer Pending
  2024-519624-24-00 4 HER3-mutant and HER2-not amplified metastatic breast cancer
• A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cel … Pending
  2024-519786-22-01 9 metastatic non-small cell lung cancer (NSCLC)
• Evaluation study of a treatement with Nivolumab and Ipilimumab or tKi according to molecular group in naïve metastatic Kidney cancer Pending
  2024-520045-23-00 4 Kidney cancer
• Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously unt … Pending
  2025-521199-80-00 4 Patients with previously untreated symptomatic chronic lymphocytic leu
• Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad … Pending
  2025-521221-32-00 5 Advanced or Metastatic Non-Small Cell Lung Cancer
• A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu … Pending
  2025-521587-35-00 5 Metastatic colorectal cancer
• Study evaluating two treatment strategies for rectal cancer in patients ≥75 years old Pending
  2025-521619-37-00 5 Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to r
• Testing two different drugs (sacituzumab-govitecan and trastuzumab-deruxtecan) combinations prescribed in an alterning pattern to patients w … Pending
  2025-521909-40-00 4 Patients with metastatic or locally advanced HER2-low triple-negative
• Clinical trial evaluating the biological activity of a new drug identified as prifetrastat (PF-07248144), combined with fulvestrant for the … Pending
  2025-521982-29-00 4 Adult patients with advanced hormone receptor positive (HR+), HER2- br
• METAREM / META-1 - METAREM :Immunotherapy Master Trial for Advanced Cancers / META-1: Immunotherapy without chemotherapy for advanced lung c … Pending
  2025-522655-26-00 4 METAREM:Patients with advanced cancer, as defined as unresectable loca
• A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Pending
  2025-523586-18-00 5 Non-Small Cell Lung Cancer
• Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending
  2025-523683-20-00 4 Postmenopausal patients with small (pT1a-b pN0) hormone receptor posit
• A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting
  2025-524498-17-00 10 2026-05-08 Pretreated Unresectable Locally Advanced or Metastatic human epidermal
• Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and … Recruiting
  2025-522996-27-00 5 2026-05-05 recurrent and/or metastatic squamous cell carcinoma of the head and ne
• A Study of YL201 in Combination with Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors Recruiting
  2025-523742-27-00 9 2026-04-28 Advanced solid tumors
• ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting
  2025-521884-12-00 5 2026-03-19 First line triple-negative breast cancer (TNBC)
• Trial of T-DXd Versus SoC Chemotherapy as Adjuvant Treatment in Endometrial Cancer Recruiting
  2024-519444-33-00 5 2026-03-12 HER2-expressing endometrial cancer (IHC 3+/2+)
• RAGNAR: Refractory Advanced diGestive Neuroendocrine carcinomas treated with tARlatamab Recruiting
  2024-514327-42-00 4 2025-12-18 Advanced neuroendocrine carcinomas (NECs) of the digestive system or u
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 5 2025-12-18 Patients with HR+ HER2- early breast cancer at intermediate risk of re
• A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o … Recruiting
  2023-508056-19-00 5 2025-10-02 HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P

Showing 1–24 of 288 trials